First, the wide availability of CA125 in most clinical laboratories, its measurement following standardized and reproducible methods, and low cost (< 2.5 € per determination) make this marker attractive for routine use in decompensated HF and other diseases. This evidence concerns the gene MUC16 and hydrops fetalis.